Cytokinetics (CYTK)

Quick facts

Phase 3 pipeline

• Omecamtiv Mecarbil (OM) · Cardiovascular
  Omecamtiv mecarbil is a cardiac myosin activator that directly enhances the force of heart muscle contraction by increasing the number of myosin heads that generate force during systole.
• Placebo to match aficamten · Cardiovascular
  This is an inert placebo formulation designed to match the physical and sensory characteristics of aficamten for blinded clinical trial purposes.

Phase 2 pipeline

• CK-2017357 · Cardiovascular
  CK-2017357 is a cardiac myosin inhibitor that increases cardiac contractility.
• Omecamtiv Mecarbil Matrix F1 Formulation
• Omecamtiv Mecarbil Matrix F2 Formulation

Phase 1 pipeline

• AMG 423
• CK-3773274 - Granules in Capsule
• CK-3773274 - Tablets
• CK-4021586

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Cytokinetics portfolio CI brief
• Cytokinetics pipeline updates RSS